New drug cocktail shows promise for Tough-to-Treat myeloma
NCT ID NCT02199665
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This early-phase study tested a combination of three drugs (selinexor, carfilzomib, and dexamethasone) in 52 adults with multiple myeloma that had returned or stopped responding to prior treatments. The main goal was to find the safest dose and identify side effects. Researchers also looked at whether the treatment could shrink or control the cancer. This is not a cure, but a way to manage the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mayo Clinic (AZ)
Scottsdale, Arizona, 85259, United States
-
Mount Sinai Medical Center
New York, New York, 10029, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109, United States
-
Wayne State University Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
Conditions
Explore the condition pages connected to this study.